Three key IP takeaways from Bayer's $7.6 billion sale of its animal health unit

Three key IP takeaways from Bayer's $7.6 billion sale of its animal health unit

The German company's divestiture to Elanco is the latest example of a pharma giant fleeing non-core business areas - and it is unlikely to be the last

Unlock unlimited access to all IAM content